Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combination of ASA and clopidogrel reduces heart attack risk in patients with acute coronary syndrome

23.04.2009
Patients particularly benefit in the early phase of treatment - however, bleeding complications occur more often

In order to better prevent blood clots, clopidogrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

The Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether the combination of clopidogrel and ASA actually has a higher benefit for patients than ASA alone. The final report by IQWiG, published on 31 March 2009, concludes that combination therapy can measurably reduce the risk of a heart attack. This particularly applies if the 2 drugs are used in the early stage of treatment.

ASA and clopidogrel should complement each other's effects

Clopidogrel is an anti-platelet drug ("platelet aggregation inhibitor”) that is used in a similar way to ASA. It inhibits parts of the blood-clotting system, leading to a reduction in platelet clotting (aggregation) and of the subsequent formation of blood clots (thrombi). Clopidogrel thus reduces the risk of occlusion of the arteries and helps prevent heart attacks and strokes. However, the risk of bleeding increases. As the mechanism that affects blood clotting is slightly different from that of ASA, clopidogrel can also be used in combination with ASA in certain cases. It is assumed the 2 drugs complement each other and that the overall inhibitory effect on the formation of blood clots increases.

The combination of clopidogrel and ASA is approved in patients with acute coronary syndrome (ACS), i.e., with an acute stenosis of the coronary blood vessels. On the one hand, this refers to patients with an acute heart attack, which is shown in the electrocardiogram (ECG) as a characteristic elevation of the ECG wave between the "S” and "T” point (ST-segment elevation myocardial infarction, STEMI). On the other hand, it refers to patients with acute severe ischaemia of the heart, but without a heart attack and the typical ST-segment elevation in the ECG. Both types of patients must as a rule immediately receive medical treatment in a hospital.

Previously unpublished data included in the assessment

IQWiG identified a total of 7 randomized controlled trials in which the effects of clopidogrel plus ASA were compared with ASA monotherapy in patients with acute coronary syndrome and which focussed on patient-relevant outcomes. For 2 of these studies, not all necessary data were available in order to interpret their results reliably. They could thus not be included in the assessment. One of these studies (CREDO) was sponsored by the company Sanofi-Aventis, which developed clopidogrel and markets the drug. However, as both studies were relatively small, it is not assumed that they would considerably affect the conclusion of the report.

Of the remaining 5 clinical comparisons, only one referred to patients with ACS without ST-segment elevation. The other studies investigated patients with STEMI/ACS. Sanofi-Aventis provided all data requested by IQWiG for the 3 largest and most important studies. In this way, essential data previously inaccessible to the public could be incorporated into the assessment.

Patients with acute coronary syndrome without ST-segment elevation: clopidogrel plus ASA has no effect on mortality

The results of the only study that could be assessed in patients with ACS without ST-segment elevation provided proof that patients using combination therapy experienced fewer heart attacks. In this study patients were treated for up to 12 months. All-cause mortality was not reduced by the additional use of clopidogrel. At the same time, major bleeding complications occurred more often than with ASA monotherapy. It cannot be conclusively assessed, on the basis of the available data, how long it is meaningful for patients to use combination therapy in order for this therapy to be more beneficial than harmful. Specific studies are lacking here. Overall, however, patients seem to particularly benefit from combination therapy in the early phase of treatment.

Combination therapy in patients with STEMI/ACS can better prevent reoccurrence of a heart attack

The evidence base is clear regarding the reoccurrence of heart attacks in patients with STEMI/ACS. The data provide proof that the additional use of clopidogrel during the stay in hospital reduces the heart attack rate more strongly than ASA alone does. However, it has so far not been proven that these patients benefit from taking both drugs after leaving the hospital. In addition, the data also provide indications that combination therapy in patients with STEMI/ACS is also more successful regarding the prevention of a stroke.

In contrast to patients with ACS without ST-segment elevation, the additional use of clopidogrel in patients with STEMI/ACS could also have a beneficial effect on all-cause mortality. In the individual studies the results were inconsistent for this outcome; however, a meta-analysis showed a reduced mortality rate, which IQWiG evaluates as an indication of a benefit.

Patients with STEMI/ACS who use clopidogrel also experience bleeding complications more often; however, these are usually minor.

The studies also show that the starting point of therapy is important for treatment success. The data provide indications that patients particularly benefit from combination therapy if treatment starts not later than 6 hours after the first occurrence of symptoms.

Procedure of report production

The preliminary results (preliminary report) were published by IQWiG at the end of September 2008 and interested persons and parties invited to submit comments. After the conclusion of the commenting procedure, the preliminary report was revised and the final report sent to the contracting agency, the Federal Joint Committee, at the beginning of February 2009. The documentation of the written comments will be published in a separate document simultaneously with the final report.

Contact: Tel ++49(0)221-35685-0, info@iqwig.de

Dr. Anna-Sabine Ernst | EurekAlert!
Further information:
http://www.iqwig.de

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Long-lived storage of a photonic qubit for worldwide teleportation

12.12.2017 | Physics and Astronomy

Multi-year submarine-canyon study challenges textbook theories about turbidity currents

12.12.2017 | Earth Sciences

Electromagnetic water cloak eliminates drag and wake

12.12.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>